Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNIPR001-IV
- Development stage
- Preclinical
- Lead developer
- SNIPR Biome
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
SNIPR001-IV is a CRISPR-based precision antimicrobial developed by SNIPR Biome, specifically an intravenous formulation of the SNIPR001 platform. It consists of a cocktail of bacteriophages engineered with CRISPR-Cas technology to selectively target and kill multidrug-resistant (MDR) Escherichia coli. The phages deliver CRISPR-Cas components into the bacteria, where they induce lethal double-stranded DNA breaks in the bacterial genome. This targeted approach is designed to treat systemic infections such as sepsis and kidney transplant-related infections, as well as uncomplicated urinary tract infections, while sparing the commensal microbiome. SNIPR001-IV is currently in the IND-enabling phase of development.
02
Targets
Escherichia coli outer membrane receptors (E. coli OMRs)bacterial dsDNA (Bacterial double-stranded DNA)
Beyond the preview
Go deeper on SNIPR001-IV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNIPR001-IV.